Retina

Imaging can elucidate visual prognosis and disease progression risk.

In this first study to provide an in-depth analysis of the retinal proteins, researchers conducted histopathologic and biochemical studies of postmortem retina and brain tissues from 86 human donors.

These disorders account for most of the vision loss in working-age and elderly Americans.

Mohammad Rafieetary, OD, shares key highlights from his VEE 2023 presentation looking at what's hot in retina.

Paul Chous, MA, OD, FAAO, shares key highlights from his 2023 SECO presentation looking at sleep disorders and how they play a role in eye disease.

Andy Lee, MD, gives highlights from his SECO special session, "Neuro nuggets."

Mohammed Rafieetary, OD, shares key takeaways from his SECO 2023 presentation, "Advancing the understanding of geographic atrophy."

Paul Chous, MA, OD, FAAO, gives key takeaways from his 2023 SECO presentation on diabetes: then and now.

The Biologics License Application for aflibercept 8 mg was supported by positive data from the PULSAR study, investigating wet AMD, and the PHOTON study, investigating DME.

Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.

Aflibercept, a VEGF inhibitor previously indicated for a variety of retinal diseases, is the first pharmacological treatment for retinopathy of prematurity in preterm infants.

The trial showed no added benefit of nesvacumab and aflibercept combination therapy over aflibercept monotherapy.

These results emphasize the importance of evaluating the midperipheral and peripheral retina in diabetes in addition to the posterior pole and performing ultra-widefield fluorescein angiography for not only accurate diabetic retinopathy staging, but also for likelihood of significant progression based on disease severity and predominantly peripheral lesions.

Leo Semes, OD, FAAO, shares key highlights from his EyeCon 2022 presentation, "Advances in therapies for retinal disease."

Look out for at-risk patients and prepare to establish treatment protocols.

Denise A. Valenti, OD, FAAO, gives key takeaways from her AAOpt 2022 discussion on the impact of marijuana use and driving.

Multiple sclerosis is a neurodegenerative disease with ophthalmic manifestations. Although some cases come to attention following an attack of optic neuritis, embedded optic atrophy can be observed in other, longer-standing cases.

Justin Schweitzer, OD, gives a brief overview of his EyeCon 2022 presentations, reflecting on pipeline advancements made in optometry in 2022.

Case history can give clues to a patient’s risk of developing diabetic eye disease.

Parres Wright, OD, FAAO, shares highlights from her discussion, "Diabetes and low vision rehabilitation," which she presented during AAOpt 2022.

The ERG is a game changer for patients with diabetes.

Teplizumab may work by binding to certain immune system cells that attack insulin-producing cells and increase the proportion of cells that help moderate the immune response, thus delaying progression to stage 3 type 1 diabetes.

Sherrol A. Reynolds, OD, FAAO, shares highlights from her discussion, "The OD's role in addressing silent killers: diabetes, hypertension, and dyslipidemia," which she presented during this year's American Academy of Optometry annual meeting.

Brad Sutton, OD, FAAO, FORS, shares highlights from his discussion titled, "Retinal imaging grand rounds," which he co-presented during the 2022 American Academy of Optometry meeting.

Anthony DeWilde, OD, FAAO, shares highlights from his AAOpt presentation, "Anti-VEGF and the eye: Past, present and future."